GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
GLAUKOS Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$166.96+2.12 (+1.29%)
Close on Oct 19, 2026
- Market cap
- $9.82B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$79.79 (+91.53%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
GLAUKOS Corp grew revenue 41.5% to $612.84M over the twelve months to Jun 30, 2026. Free cash flow was -$12.20M.
Revenue
$612.84M
+41.5% vs. a year earlier
Operating income
-$193.36M
TTM Q2 2026
Free cash flow
-$12.20M
TTM Q2 2026
EPS, diluted
-$3.25
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.82B
- P/E ratio
- –
- Price to sales
- 16.02
- Price to book
- 14.39
- Dividend yield
- –
- Free cash flow yield
- -0.12%
Fundamentals
- Revenue
- $612.84M
- Net income
- -$188.05M
- EPS, diluted
- -$3.25
- Free cash flow
- -$12.20M
- Book value per share
- $11.60
- Diluted shares
- 59M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$612.84M+41.5% YoY
Gross profit
$372.02M+12.6% YoY
Operating income
-$193.36M
Net income
-$188.05M
EPS, diluted
-$3.25
Free cash flow
-$12.20M
Reported periodTrailing twelve months